"A rare pancreatic schwannoma, initially mistaken for a cancerous neuroendocrine tumor due to internal bleeding, underscores the critical role of pathological examination in diagnosing pancreatic masses, even with advanced imaging."
A recent clinical case report from Japan has illuminated a diagnostic challenge in oncology, detailing the experience of a 67-year-old woman whose pancreatic mass was initially suspected to be a pancreatic neuroendocrine tumor (pNET) but was ultimately identified as a far rarer, typically benign schwannoma. The discovery of the 31 by 23-millimeter mass in her pancreas was serendipitous, occurring during a CT scan performed to investigate an unrelated abnormal spot on her lung. This incident highlights how incidental findings can lead to complex diagnostic pathways and emphasizes that while advanced imaging techniques are invaluable, the definitive diagnosis often rests with microscopic examination of tissue. The case, published in Oxford Medical Case Reports, serves as a reminder of the diverse pathological landscape within the pancreas and the potential for rare conditions to present in ways that mimic more common or aggressive diseases.
The initial suspicion of a pancreatic neuroendocrine tumor arose from the mass’s appearance on a contrast-enhanced CT scan. The growth displayed sharp, well-defined borders, but its internal structure was notably patchy, featuring darker areas interspersed throughout. As the scan progressed and contrast dye was administered, the tumor’s edges showed increased uptake, and several small internal spots exhibited a brightness comparable to nearby blood vessels. This imaging signature is characteristic of pNETs, which originate from the hormone-producing cells of the pancreas. These tumors, though uncommon, can be malignant. The National Cancer Institute estimates that pNETs account for less than 2% of all pancreatic malignancies in the United States, with approximately 1,000 new cases diagnosed annually.
The patient in this case did not present with any specific symptoms directly attributable to the pancreatic mass. Her medical attention was drawn by the incidental finding of an abnormal lung opacity, the nature of which was not detailed in the report. This underscores the significant role of routine screening and diagnostic imaging in uncovering unexpected pathologies.
In an effort to refine the diagnosis before proceeding to surgery, the medical team employed two specialized nuclear medicine scans. The first was a somatostatin receptor scan, a common tool for detecting neuroendocrine tumors, as many pNETs express somatostatin receptors. However, this scan returned negative results for the patient’s pancreatic mass. While a negative somatostatin receptor scan can help rule out certain types of neuroendocrine tumors, it is not entirely conclusive, as some subtypes, like insulinomas, may exhibit fewer of these receptors.
The second nuclear medicine test involved a scan using a tracer known as MIBG (meta-iodobenzylguanidine). This scan showed only faint uptake of the tracer. The National Cancer Institute notes that MIBG scans are primarily used to detect neuroendocrine tumors like paragangliomas, some of which are known to overproduce hormones such as adrenaline and noradrenaline. Following an endocrinology consultation, a hormone-producing paraganglioma was deemed unlikely given the overall clinical picture and the scan results.
Collectively, these nuclear medicine scans diminished the likelihood of both pNET and paraganglioma but did not provide a definitive diagnosis. Consequently, the surgical team proceeded with a laparoscopic enucleation. This minimally invasive surgical approach involves carefully removing the tumor while preserving the surrounding pancreatic tissue, a critical consideration for maintaining organ function.
The true nature of the tumor was revealed only after its surgical removal and subsequent examination by pathologists. Under microscopic analysis, the well-defined mass was found to contain extensive internal bleeding and areas of degeneration. The pathologists identified characteristic cellular patterns: wavy, spindle-shaped cells arranged in alternating dense (Antoni A) and loose (Antoni B) areas. This histological pattern is a classic hallmark of schwannoma. Furthermore, the cells showed no significant atypia (abnormal cell changes) or signs of rapid proliferation, indicating a benign nature. Immunohistochemical staining further corroborated the diagnosis. The tumor tested positive for S100 protein, a marker commonly found in Schwann cells, and negative for synaptophysin, chromogranin A, and INSM1, which are typically used to identify neuroendocrine tumors.
Schwannomas originate from Schwann cells, the cells responsible for forming the myelin sheath that insulates peripheral nerves. According to the Mayo Clinic, schwannoma is the most common type of benign peripheral nerve tumor found in adults, and malignant transformation is exceedingly rare.
The patient experienced an uncomplicated recovery following the surgery and was discharged from the hospital seven days after the procedure. Her case, however, highlights the diagnostic challenges posed by schwannomas, particularly when they occur in unusual locations like the pancreas.
The occurrence of a schwannoma within the pancreas is exceptionally rare. Authors of the report categorize it as an "extremely rare tumor," accounting for approximately 0.03% of all pancreatic tumors. This rarity contributes significantly to the diagnostic difficulty, as clinicians are less likely to consider it as a primary diagnosis when faced with a pancreatic mass. The report explicitly states that "the preoperative diagnosis of PS [pancreatic schwannoma] is challenging because it frequently mimics other pancreatic neoplasms." A 2019 review published in Pancreatology by Zhang and colleagues found that a substantial 29% of patients diagnosed with pancreatic schwannoma had initially received a preoperative diagnosis of pNET.
The authors of the current report explained how the bleeding within the schwannoma led to the diagnostic confusion. Schwannomas can develop internal bleeding or form cystic areas as they undergo degeneration. Similarly, pNETs can also exhibit areas of necrosis, or dead tissue. In this particular patient’s case, the heavy internal hemorrhage within the schwannoma created an uneven, heterogeneous appearance on the CT scan that closely resembled a pNET with internal necrotic changes.
While this single case report provides valuable insight, it is important to acknowledge its limitations. A single patient’s experience cannot definitively establish the frequency with which bleeding within schwannomas leads to misdiagnosis or dictate changes in imaging practices. Nevertheless, it powerfully illustrates why a thorough pathological examination remains the ultimate arbiter for certain pancreatic masses, even in the era of advanced diagnostic imaging.
For the general public, the key takeaway from such cases is not to assume that any incidentally discovered pancreatic mass is likely to be benign. The pancreas is a complex organ, and growths within it can have a wide range of etiologies, some of which are highly serious. The appropriate diagnostic workup is highly individualized and depends on a multitude of factors unique to each patient. Individuals who receive news of an unexpected finding on a scan should engage in a detailed discussion with their healthcare provider to fully understand the potential implications and the recommended follow-up course of action. This collaborative approach ensures that patients are well-informed and that diagnostic and treatment pathways are tailored to their specific circumstances.
